Meningiomas May Be a Component Tumor of Multiple Endocrine Neoplasia Type 1

• Published in: Clinical cancer research 2004-02, Vol.10 (3), p.869-880
• Main Authors: ASGHARIAN, Behnam, CHEN, Yuan-Jia, PATRONAS, Nicholas J, PEGHINI, Paolo L, REYNOLDS, James C, VORTMEYER, Alexander, ZHENGPING ZHUANG, VENZON, David J, GIBRIL, Fathia, JENSEN, Robert T
• Format: Article
• Language: English
• Subjects: Adult; Alleles; Antineoplastic agents; Biological and medical sciences; Brain - pathology; Chromosomes - ultrastructure; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 22; DNA-Binding Proteins - genetics; Fathers; Female; Genes, Tumor Suppressor; Humans; Loss of Heterozygosity; Magnetic Resonance Imaging; Male; Medical sciences; Meningioma - metabolism; Meningioma - pathology; Microsatellite Repeats; Middle Aged; Mothers; Multiple Endocrine Neoplasia Type 1 - pathology; Neurofibromin 2 - genetics; Nuclear Proteins - genetics; Pancreatic Neoplasms - pathology; Pharmacology. Drug treatments; Polymerase Chain Reaction; Prospective Studies; Tomography, X-Ray Computed; Tumor Protein p73; Tumor Suppressor Proteins; Tumors; Zollinger-Ellison Syndrome - genetics
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-0938-3

Purpose: Recently, an increased incidence of some nonendocrine tumors are reported in patients with multiple endocrine neoplasia type 1 (MEN 1). There are rare reports of meningiomas and other central nervous system tumors in these patients, but it is unknown if they are more frequent or if allelic loss of the MEN1 gene is important in their pathogenesis. The aim of this study was to address these two latter questions. Experimental Design: Results from a prospective study of 74 MEN 1 patients with suspected/proven pancreatic endocrine tumors (PETs) were analyzed, as well as molecular studies performed on a resected meningioma. All patients had serial brain imaging studies (computed tomography, magnetic resonance imaging, and octreoscanning since 1994) and yearly studies evaluating MEN 1 involvement with a mean follow-up of 7.2 years. Results were compared with 185 patients with sporadic Zollinger-Ellison syndrome. Results: Six patients (8%) had meningiomas. Meningiomas were single and found late in the MEN 1 course (mean age = 51 years). Magnetic resonance imaging/computed tomography were more sensitive than octreoscanning. Their diagnosis averaged 18 years after the onset of hyperparathyroidism, 10–15 years after pituitary disease or PETs. Meningiomas were 11 times more frequent in patients with PETs with MEN 1 than without MEN 1 ( P = 0.017). No clinical, laboratory, or MEN 1 feature distinguished patients with meningiomas. Meningiomas were asymptomatic and 60% showed no growth. A resected meningioma showed loss of heterozygosity at 11q13 and 1p, including at p73 and ARHI/NOEY2 locus, but not at the neurofibromatosis 2 gene locus. Conclusions: These results show meningiomas are not an infrequent occurrence in MEN 1, and loss of the function of the MEN1 gene product plays a role in their pathogenesis in these patients.